John Libbey Eurotext

Hématologie

Adjonction du bortézomib à l’association lénalidomide-dexaméthasone dans le myélome multiple sans indication première à l’autogreffe de cellules souches hématopoïétiques Volume 23, numéro 2, Mars-Avril 2017

  • [1] Kumar S.K., Dispenzieri A., Lacy M.Q. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28:1122-1128.
  • [2] Rajkumar S.V., Kumar S.K. Multiple myeloma: diagnosis and treatment. Mayo Clin Proc. 2016;91:101-119.
  • [3] Mitsiades N., Mitsiades C.S., Poulaki V. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood. 2002;99:4525-4530.
  • [4] Durie B., Hoering A., Abidi M. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017;389:519-527.